Effect of Symbicort nasal exhalation for eosinophilic rhinosinusitis with bronchial asthma
Not Applicable
Recruiting
- Conditions
- eosinophilic rhinosinusitis bronchial asthma
- Registration Number
- JPRN-UMIN000028765
- Lead Sponsor
- Department of Allergy and pulmonary medicine, Mitsubishi Kyoto Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) intranasal steroid, systemic corticosteroid, depo-triamcinolone, Shinni-Seihai Tou, mepolizumab are prescribed. 2)Systemic steroid prescribed twice or more within one month. 3)Omalizumab or LTRA is begun within 6 month. 4)Who has a complication considered to affect the evaluation of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of Lund-Mackay CT score three month after the intervention
- Secondary Outcome Measures
Name Time Method %FEV1.0, %MMEF, percentage of peripheral blood eosinophil, Asthma Control Test (ACT), symptom scores of disturbance of smell and nasal obstruction